Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
fda
indiana blog main
indiana top stories
life sciences
national blog main
2
×
new york blog main
new york top stories
alex azar
alirocumab
american patients first
biosimilars
boehringer ingelheim
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
center for medicare and medicaid services
clinical trials
craig garthwaite
cvs health
department of health and human services
detroit blog main
detroit top stories
donald trump
drug prices
eli lilly
empagliflozin
europe
europe blog main
europe top stories
express scripts
food and drug administration
generic drugs
health insurance
medicare
national
national top stories
northwestern university
pharmaceutical care management association
What
drug
short
2
×
afternoon
anticipated
approval
awaited
bid
blueprint
boehringer
cost
cut
details
diabetes
drugs
eli
expand
fallen
fda
house
ingelheim
lilly
long
lower
marketed
meant
medicine’s
patients
plan
pledges
prescription
president
prices
rejects
speech
trump
type
unveiled
white
Language
unset
Current search:
short
×
" national blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details